DFG funds study by Roman-Ullrich Müller on treatment of the most common genetic kidney disease

27/11/2024

STOP-PKD is the first study to evaluate the safety and efficacy of SGLT2 inhibitors in patients with ADPKD.

Prof. Dr. Roman-Ulrich Müller, Christian Wittke - Foto: Klaus Schmidt

Prof. Dr. Roman-Ulrich Müller, Professor of Translational Nephrology and spokesperson for the Center for Rare and Hereditary Kidney Diseases (ZSEN) and an associated researcher at the Center for Molecular Medicine Cologne (CMMC), has received funding from the German Research Foundation (DFG) for a multicentre drug trial. The STOP-PKD study, coordinated jointly with Dr. Philipp Scherrer, will investigate the use of SGLT2 inhibitors in patients with autosomal dominant polycystic kidney disease (ADPKD).

ADPKD is a genetic disease that leads to the development of large cystic kidneys and progressive loss of kidney function. Patients usually require some form of renal replacement therapy (dialysis, kidney transplant) by the age of 50 to 60. SGLT2 inhibitors have become an indispensable part of medicine, significantly improving the prognosis not only of chronic kidney disease but also of diabetes and heart failure. Until now, patients with ADPKD have been excluded from registration trials for the treatment of chronic kidney disease. As there are very limited treatment options for ADPKD, the STOP-PKD study aims to evaluate the safety and efficacy of SGLT2 inhibitors in adults with ADPKD. The investigator-initiated study will be conducted as a randomized, placebo-controlled, double-blind, multicenter trial with the highest quality standards at 18 German and six European sites. The DFG is supporting the six-year project of Prof. Müller and his team with more than three million euros in the first three years. Follow-up funding for the next three years is already planned.


Scientific contact
Professor Dr Roman-Ulrich Müller
roman-ulrich.mueller[at]uk-koeln.de


This article is based on the news presented by press and communications team of the University Hospital Cologne (original German version here) and has been modified by the CMMC Communication Team (K. Heber & D. Grosskopf-Kroiher).